A China-based early stage fund focused on angel investment and incubation in the healthcare field is currently investing from its RMB 200 M fund (USD 30 M) closed in 2015, backed by several Chinese healthcare companies. The firm’s typical investment size range from USD 1-1.5 M and is open to leading or co-investing. The firm is currently seeking opportunities in China or US-based companies with a China angle.
The firm is looking for cutting edge platform technologies in sectors including therapeutics, medical devices, and diagnostics. The firm is agnostic to therapeutic indications. In terms of development stage, the firm focuses on startup teams with some preclinical validation.
The firm is looking for strong management teams with sector expertise. The firm aims to bridge between R&D and commercialization with a focus on China-based startup teams or US companies with a China angle. The firm may request a board seat on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org